Cardiovascular Disease in Patients With Diabetes: The Silesia Diabetes-Heart Project

NCT ID: NCT05626413

Last Updated: 2024-04-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

4000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-01-01

Study Completion Date

2026-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The project is an observational one which undertakes different, easy to obtain in everyday clinical practice, demographical, laboratory and clinical parameters of patients with diabetes in Silesian Region in Poland to predict cardiovascular disease, cardiovascular events and neuropathy using machine learning approach.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is a prospective, observational one in which it is planned to obtain demographical, laboratory and clinical parameters of patients who are hospitalized in one the the main diabetology sites in Silesia region in Poland and to follow them prospectively for 10 years in order to collect information related to new cardiovascular events. Telephone contact will be performed every 12 months following hospital discharge. Any procedures related to the patients hospitalized in the diabetology ward will be the routine ones and the bioethics committee of Medical University of Silesia gave the permission for the study but waved the necessity of informed consent to be signed.Moreover there will be subgroup analysis of patients recruited from the outpatient diabetology clinics in Silesia region in order to participate in the observational study collecting data related to to vitamin D concentration, densitometry, fibroscan, carotid ultrasound examination, vascular stiffness, electrocardiography, peripheral and cardiovascular autonomic neuropathy and fundus imaging. Patients who are treated in outpatient diabetology clinics in Silesia region and are included into the study must have the informed consent signed and bioethics committee agreement has been obtained.

Machine learning approach will be implemented to discover the association between easy to obtain in everyday practice parameters, namely clinical, biochemical, and demographical ones to identify patients at the highest risk of cardiovascular disease.

The secondary aim of the study is to utilize fundus imaging, electrocardiography, alongside demographic and clinical data in order to potentially diagnose neuropathy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* For the group of hospitalized patients: diabetes type 1 or type 2
* For the subgroup of patients treated in outpatient diabetology clinics in Silesia region: diabetes type 1 or type 2

Exclusion Criteria

1. For the group of hospitalized patients:

* Types of diabetes other than type 1 and type 2 diabetes
* Death during hospital stay
* Terminal stage of cancer.
2. For the subgroup of patients recruited form outpatient diabetology clinics:

* Lack of an informed consent
* Types of diabetes other than type 1 and type 2 diabetes
* Malignant neoplasms
* Terminal stage of neoplasm
* End-stage renal disease
* Malabsorption syndrome
* Active infection
* Primary hyperparathyroidism
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Silesian University of Technology

OTHER

Sponsor Role collaborator

Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital

UNKNOWN

Sponsor Role collaborator

Medical University of Silesia

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Katarzyna Nabrdalik, PhD,prof.

Role: PRINCIPAL_INVESTIGATOR

Medical University of Silesia

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Internal Diseases, Diabetology and Nephrology

Zabrze, , Poland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Poland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Katarzyna Nabrdalik, PhD, prof.

Role: CONTACT

0048697592954

Hanna Kwiendacz, PhD

Role: CONTACT

0048509774849

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Hanna Kwiendacz, MD,PhD

Role: primary

0048509774849

Katarzyna Nabrdalik, MD,PhD,prof

Role: backup

0048697592954

References

Explore related publications, articles, or registry entries linked to this study.

Janota O, Mantovani M, Kwiendacz H, Irlik K, Bucci T, Lam SHM, Huang B, Alam U, Boriani G, Hendel M, Piasnik J, Olejarz A, Wlosowicz A, Pabis P, Wojcik W, Gumprecht J, Lip GYH, Nabrdalik K. Metabolically "extremely unhealthy" obese and non-obese people with diabetes and the risk of cardiovascular adverse events: the Silesia Diabetes - Heart Project. Cardiovasc Diabetol. 2024 Sep 3;23(1):326. doi: 10.1186/s12933-024-02420-x.

Reference Type DERIVED
PMID: 39227929 (View on PubMed)

Nabrdalik K, Irlik K, Meng Y, Kwiendacz H, Piasnik J, Hendel M, Ignacy P, Kulpa J, Kegler K, Herba M, Boczek S, Hashim EB, Gao Z, Gumprecht J, Zheng Y, Lip GYH, Alam U. Artificial intelligence-based classification of cardiac autonomic neuropathy from retinal fundus images in patients with diabetes: The Silesia Diabetes Heart Study. Cardiovasc Diabetol. 2024 Aug 10;23(1):296. doi: 10.1186/s12933-024-02367-z.

Reference Type DERIVED
PMID: 39127709 (View on PubMed)

Nabrdalik K, Kwiendacz H, Irlik K, Hendel M, Drozdz K, Wijata AM, Nalepa J, Janota O, Wojcik W, Gumprecht J, Lip GYH. Machine learning identification of risk factors for heart failure in patients with diabetes mellitus with metabolic dysfunction associated steatotic liver disease (MASLD): the Silesia Diabetes-Heart Project. Cardiovasc Diabetol. 2023 Nov 20;22(1):318. doi: 10.1186/s12933-023-02014-z.

Reference Type DERIVED
PMID: 37985994 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Silesia Diabetes-Heart Project

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.